1Weinreb NJ, Andersson HC, Banikazemi M, et al. Prevalence of type 1 Gaucher disease in the United States. Arch Intern Med, 2008,168:326-327.
2Pastores GM, Hughes DA. Gaueher Disease. In: Pagon RA, Bird TC, Dolan CR, Stephens K, eds. GeneReviews. Seattle ( WA ) : University of Washington, Seattle; 1993-2000 Jul 27 [ updated 2008 Mar 13 ]. http://www, ncbi. nlm. nih. gov/books/ NBK1269.
3Andersson HC, Charrow J, Kaplan P, et al. Individualization of long term enzyme replacement therapy for Gaucher disease. Genet Med ,2005,7:105-110.
4Weinreb NJ,Barranger JA, Charrow J, et al. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol, 2005,80:223-229.
5Cox TM. Eliglustat tartrate, an orally active glucocerebmside synthase inhibitor for the potential treatment of Gaucher disease and other lysosomal storage diseases. Curt Opin Investig Drugs, 2010,11:1169-1181.
6Suzuki Y, Ogawa S, Sakakibara Y. Chaperone therapy for neuronopathic lysosomal diseases : competitive inhibitors as chemical chaperones for enhancement of mutant enzyme activities. Perspect Mediein Chem,2009 ,26 :7-19.
7Beck M. Therapy for lysosomal storage disorders. IUBMB Life, 2010,62:33-40.
8Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med,1998 ,158 :1754-1760.
9Weinreb N J, Aggio MC, Andersson HC, et al. Gaucher Disease Type 1 :revised recommendations on evaluation and monitoring for adult patients. Semin Hematol,2004, 41 : 15-22.
10Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic Goals in the Treatment of Gaucher Disease. Semin Hematol.2004. 41,4-14.
